These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

724 related articles for article (PubMed ID: 12637461)

  • 81. Is adjuvant tamoxifen recommended in post-menopausal node-negative breast cancer patients with high estrogen receptor values?
    Floiras JL; Hacene K; Turpin F; Spyratos F
    Int J Biol Markers; 2000; 15(2):135-8. PubMed ID: 10883886
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients: results of French Adjuvant Study Group 02 and 07 trials.
    Namer M; Fargeot P; Roché H; Campone M; Kerbrat P; Romestaing P; Monnier A; Luporsi E; Montcuquet P; Bonneterre J;
    Ann Oncol; 2006 Jan; 17(1):65-73. PubMed ID: 16361531
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer.
    Han W; Han MR; Kang JJ; Bae JY; Lee JH; Bae YJ; Lee JE; Shin HJ; Hwang KT; Hwang SE; Kim SW; Noh DY
    BMC Cancer; 2006 Apr; 6():92. PubMed ID: 16608533
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Risk of Recurrence or Contralateral Breast Cancer More than 5 Years After Diagnosis of Hormone Receptor-Positive Early-Stage Breast Cancer.
    Wilson S; Speers C; Tyldesley S; Chia S; Kennecke H; Ellard S; Lohrisch C
    Clin Breast Cancer; 2016 Aug; 16(4):284-90. PubMed ID: 26705158
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Direct comparisons of adjuvant endocrine therapy, chemotherapy, and chemoendocrine therapy for operable breast cancer patients stratified by estrogen receptor and menopausal status.
    Nomura Y; Shirouzu M; Takayama T
    Breast Cancer Res Treat; 1998 May; 49(1):51-60. PubMed ID: 9694611
    [TBL] [Abstract][Full Text] [Related]  

  • 86. A randomised trial of tamoxifen versus tamoxifen with aminoglutethimide in post-menopausal women with advanced breast cancer.
    Milsted R; Habeshaw T; Kaye S; Sangster G; Macbeth F; Campbell-Ferguson J; Smith D; Calman K
    Cancer Chemother Pharmacol; 1985; 14(3):272-3. PubMed ID: 3888433
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial.
    Howell A; Robertson JF; Abram P; Lichinitser MR; Elledge R; Bajetta E; Watanabe T; Morris C; Webster A; Dimery I; Osborne CK
    J Clin Oncol; 2004 May; 22(9):1605-13. PubMed ID: 15117982
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Physical activity and survival of postmenopausal, hormone receptor-positive breast cancer patients: results of the Tamoxifen Exemestane Adjuvant Multicenter Lifestyle study.
    de Glas NA; Fontein DB; Bastiaannet E; Pijpe A; De Craen AJ; Liefers GJ; Nortier HJ; de Haes HJ; van de Velde CJ; van Leeuwen FE
    Cancer; 2014 Sep; 120(18):2847-54. PubMed ID: 24840230
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study.
    Borgquist S; Giobbie-Hurder A; Ahern TP; Garber JE; Colleoni M; Láng I; Debled M; Ejlertsen B; von Moos R; Smith I; Coates AS; Goldhirsch A; Rabaglio M; Price KN; Gelber RD; Regan MM; Thürlimann B
    J Clin Oncol; 2017 Apr; 35(11):1179-1188. PubMed ID: 28380313
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study.
    Bertelsen L; Bernstein L; Olsen JH; Mellemkjaer L; Haile RW; Lynch CF; Malone KE; Anton-Culver H; Christensen J; Langholz B; Thomas DC; Begg CB; Capanu M; Ejlertsen B; Stovall M; Boice JD; Shore RE; ; Bernstein JL
    J Natl Cancer Inst; 2008 Jan; 100(1):32-40. PubMed ID: 18159070
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Survival Outcome of Combined GnRH Agonist and Tamoxifen Is Comparable to That of Sequential Adriamycin and Cyclophosphamide Chemotherapy Plus Tamoxifen in Premenopausal Patients with Lymph-Node-Negative, Hormone-Responsive, HER2-Negative, T1-T2 Breast Cancer.
    Sohn G; Ahn SH; Kim HJ; Son BH; Lee JW; Ko BS; Lee Y; Lee SB; Baek S
    Cancer Res Treat; 2016 Oct; 48(4):1351-1362. PubMed ID: 27063654
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Randomized controlled trial comparing oral doxifluridine plus oral cyclophosphamide with doxifluridine alone in women with node-positive breast cancer after primary surgery.
    Tominaga T; Koyama H; Toge T; Miura S; Sugimachi K; Yamaguchi S; Hirata K; Monden Y; Nomura Y; Toi M; Kimijima I; Noguchi S; Sonoo H; Asaishi K; Ikeda T; Morimoto T; Ota J; Ohashi Y; Abe O
    J Clin Oncol; 2003 Mar; 21(6):991-8. PubMed ID: 12637462
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients.
    Knoop AS; Bentzen SM; Nielsen MM; Rasmussen BB; Rose C
    J Clin Oncol; 2001 Jul; 19(14):3376-84. PubMed ID: 11454885
    [TBL] [Abstract][Full Text] [Related]  

  • 94. [Current issues in adjuvant hormone therapy of breast cancer].
    Semiglazov VF; Semiglazov VV
    Vopr Onkol; 2003; 49(6):771-5. PubMed ID: 14976929
    [No Abstract]   [Full Text] [Related]  

  • 95. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer.
    Hayes DF; Van Zyl JA; Hacking A; Goedhals L; Bezwoda WR; Mailliard JA; Jones SE; Vogel CL; Berris RF; Shemano I
    J Clin Oncol; 1995 Oct; 13(10):2556-66. PubMed ID: 7595707
    [TBL] [Abstract][Full Text] [Related]  

  • 96. A phase II evaluation of combination chemotherapy plus aminoglutethimide in women with metastatic or recurrent breast carcinoma. An Eastern Cooperative Oncology Group Pilot Study.
    Grem JL; Falkson G; Love RR; Tormey DC
    Am J Clin Oncol; 1988 Oct; 11(5):528-34. PubMed ID: 3177253
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Treatment of disseminated breast cancer with tamoxifen, aminoglutethimide, hydrocortisone, and danazol, used in combination or sequentially.
    Powles TJ; Ashley S; Ford HT; Gazet JC; Nash AG; Neville AM; Coombes RC
    Lancet; 1984 Jun; 1(8391):1369-73. PubMed ID: 6145832
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Re: Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999.
    Jordan VC; Morrow M
    J Natl Cancer Inst; 2003 May; 95(9):683-4; author reply 684-5. PubMed ID: 12734320
    [No Abstract]   [Full Text] [Related]  

  • 99. Déjà vu for breast cancer two?
    Stearns V; Davidson NE
    J Natl Cancer Inst; 2004 Apr; 96(7):497-9. PubMed ID: 15069104
    [No Abstract]   [Full Text] [Related]  

  • 100. Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian-New Zealand Breast Cancer Trials Group.
    Byrne MJ; Gebski V; Forbes J; Tattersall MH; Simes RJ; Coates AS; Dewar J; Lunn M; Flower C; Gill PG; Stewart J
    J Clin Oncol; 1997 Sep; 15(9):3141-8. PubMed ID: 9294477
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.